Avoid common mistakes on your manuscript.
Correction to: Investigational New Drugs (2022) 40:1125–1132
Corrections are needed to the original publication.
1. An article note has been added. Second author Jinhua Song is the co-lead author.
2. Page 1, Abstract section, the 1st sentence under Methods sub-section should read “Enrolled in this retrospective study were patients with unresectable ICC who received TACE-L between June 2019 and December 2020” (January 2015 and May 2018 was changed to June 2019 and December 2020).
3. Page 2, Materials and Methods, second to the last sentence under Patient selection should read “The study was approved by the institutional review board of Zhongda Hospital affiliated to the Southeast University School of Medicine (Nanjing, China) and The First Affiliated Hospital of Nanjing Medical University (Nanjing, China), and carried out in accordance with the Helsinki Declaration (as revised in 2013)” (and The First Affiliated Hospital of Nanjing Medical University (Nanjing, China) has been added.
The authors apologize for corrections and further state that changes to the text does not affect the overall outcome of the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s10637-022-01257-z.
Song Jinhua is the co-lead author.
Rights and permissions
About this article
Cite this article
Yuan, P., Song, J., Wang, F. et al. Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs 41, 182 (2023). https://doi.org/10.1007/s10637-022-01323-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-022-01323-6